Suppr超能文献

血管加压素的羧基末端是活性所必需的,但不是结合所必需的。

Carboxy terminus of vasopressin required for activity but not binding.

作者信息

Manning M, Olma A, Klis W, Kolodziejczyk A, Nawrocka E, Misicka A, Seto J, Sawyer W H

出版信息

Nature. 1984;308(5960):652-3. doi: 10.1038/308652a0.

Abstract

Vasopressin antagonists are valuable pharmacological tools for investigating physiological and behavioural functions of the nonapeptide arginine-vasopressin (AVP). The removal of glycinamide from the carboxy terminus of AVP drastically reduces its characteristic vasopressor and antidiuretic activities. In contrast to this we show here that removal of the carboxy-terminal glycinamide or the glycine at position 9 from several vasopressin antagonists makes little difference to their ability to block vasopressor and antidiuretic responses to AVP. These data demonstrate the critical structural requirements of the carboxy-terminal position for receptor activation, in contrast to the lack of such requirements for receptor binding. They also provide an avenue to a wide variety of antagonists substituted at the carboxy terminus (for example radiolabelled derivatives and affinity ligands) and suggest clues for the development of more potent and/or selective antagonists.

摘要

血管加压素拮抗剂是研究九肽精氨酸血管加压素(AVP)生理和行为功能的重要药理学工具。从AVP的羧基末端去除甘氨酰胺会大大降低其特征性的血管升压和抗利尿活性。与此相反,我们在此表明,从几种血管加压素拮抗剂中去除羧基末端的甘氨酰胺或第9位的甘氨酸,对它们阻断对AVP的血管升压和抗利尿反应的能力影响不大。这些数据证明了羧基末端位置对于受体激活的关键结构要求,这与受体结合缺乏此类要求形成对比。它们还为开发各种在羧基末端进行取代的拮抗剂(例如放射性标记衍生物和亲和配体)提供了途径,并为开发更有效和/或更具选择性的拮抗剂提供了线索。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验